- Home
- CHRS vs KNOP Comparison
CHRS vs KNOP Comparison
Compare CHRS & KNOP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- KNOP
- Stock Information
- Founded
- CHRS 2010
- KNOP 2013
- Country
- CHRS United States
- KNOP United Kingdom
- Employees
- CHRS N/A
- KNOP 874
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- KNOP Marine Transportation
- Sector
- CHRS Health Care
- KNOP Consumer Discretionary
- Exchange
- CHRS Nasdaq
- KNOP Nasdaq
- Market Cap
- CHRS 84.2M
- KNOP 243.2M
- IPO Year
- CHRS 2014
- KNOP 2013
- Fundamental
- Price
- CHRS $0.90
- KNOP $6.97
- Analyst Decision
- CHRS Buy
- KNOP
- Analyst Count
- CHRS 3
- KNOP 0
- Target Price
- CHRS $4.68
- KNOP N/A
- AVG Volume (30 Days)
- CHRS 1.2M
- KNOP 61.1K
- Earning Date
- CHRS 08-07-2025
- KNOP 09-02-2025
- Dividend Yield
- CHRS N/A
- KNOP 1.48%
- EPS Growth
- CHRS N/A
- KNOP N/A
- EPS
- CHRS N/A
- KNOP 0.19
- Revenue
- CHRS $272,251,000.00
- KNOP $320,026,000.00
- Revenue This Year
- CHRS N/A
- KNOP $9.28
- Revenue Next Year
- CHRS $106.56
- KNOP N/A
- P/E Ratio
- CHRS N/A
- KNOP $36.54
- Revenue Growth
- CHRS 19.87
- KNOP 8.76
- 52 Week Low
- CHRS $0.66
- KNOP $5.28
- 52 Week High
- CHRS $2.43
- KNOP $8.15
- Technical
- Relative Strength Index (RSI)
- CHRS 59.04
- KNOP 60.20
- Support Level
- CHRS $0.73
- KNOP $6.29
- Resistance Level
- CHRS $0.82
- KNOP $7.21
- Average True Range (ATR)
- CHRS 0.04
- KNOP 0.24
- MACD
- CHRS 0.02
- KNOP 0.05
- Stochastic Oscillator
- CHRS 88.02
- KNOP 77.14
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About KNOP KNOT Offshore Partners LP Common Units representing Limited Partner Interests
KNOT Offshore Partners LP owns, operates, and shuttles tankers under long-term charters in the North Sea and Brazil. The company provides crude oil loading, transportation, and storage services under time charters and bareboat charters. The Partnership is formed for acquiring ownership interests in over four shuttle tankers owned by Knutsen NYK Offshore Tankers AS (KNOT). It operates through the shuttle tanker market segment.